Clinical Trial Update: Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cemiplimab plus CDX-1140 given before surgery to determine if the combination improves outcomes versus cemiplimab alone in Stage III-IV…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Nasal Cavity Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CDX-1140
• Libtayo (cemiplimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING